Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 269 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Methylphenidate HCl Clear all
Terminated Phase 3 Interventional Results available

Intervention for Teens With ADHD and Substance Use

NCT02502799
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
12 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

NCT00141063
View directory record Official record
Conditions
ADHD
Interventions
Focalin XR
Drug
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Hallucinogens and Other Drugs on Mood and Performance

NCT02033707
View directory record Official record
Conditions
Healthy
Interventions
Hallucinogens and psychoactive substances
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 2 Interventional Results available

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Dopamine Function in Adults With ADHD

NCT00580814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Experimental: methylphenidate treatment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Newport Beach, California • Marshfield, Massachusetts • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

NCT01259492
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Placebo, Ritalin LA 20 mg, Ritalin LA 30 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsule, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 20, 2026, 6:15 AM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 20, 2026, 6:15 AM EDT
Enrolling by invitation Phase 4 Interventional

Precision Care for Major Depressive Disorder

NCT06580041
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Major
Interventions
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
Drug · Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label, Normal Healthy Volunteer Clinical Trial of a Novel Ondansetron Formulation

NCT01290276
View directory record Official record
Conditions
Healthy
Interventions
Ond-PR1, Ond-PR1 + MPh-IR, Ond-PR2, Ond-PR2 +_ MPh-IR
Drug
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 20, 2026, 6:15 AM EDT
Terminated No phase listed Observational

Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics

NCT00247689
View directory record Official record
Conditions
Substance Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 20, 2026, 6:15 AM EDT
Terminated Phase 1 Interventional Results available

Methylphenidate for Cancer-Related Fatigue

NCT01164956
View directory record Official record
Conditions
Cancer
Interventions
methylphenidate, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
7 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 20, 2026, 6:15 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

NCT04421248
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Combined
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Donald Gilbert, MD, MS, FAAN, FAAP
Other
Eligibility
8 Years to 12 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00253747
View directory record Official record
Conditions
ADHD, Smoking
Interventions
Osmotic-Release Methylphenidate, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Early Phase 1 Interventional

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

NCT02879136
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
Methylphenidate, Physical Therapy, Atomoxetine
Drug · Other
Lead sponsor
Hubert Fernandez
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Not applicable Interventional Results available

Role of Apathy in the Effectiveness of Weight Loss Interventions

NCT00548652
View directory record Official record
Conditions
Obesity, Apathy
Interventions
MOVE, medical crisis councelling, methyphenidate
Behavioral · Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Results available

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

NCT03292952
View directory record Official record
Conditions
ADHD
Interventions
KP415 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A PET Study Examining Pharmacokinetics and Dopamine Transporter Receptor Occupancy Of Two Long-Acting Formulations of Methylphenidate in Adults

NCT00301639
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OROS methylphenidate hydrochloride, methylphenidate hydrochloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 20, 2026, 6:15 AM EDT
Completed Phase 2 Interventional

Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5

NCT00015223
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 20, 2026, 6:15 AM EDT
Not listed Not applicable Interventional

Enhancing ADHD Driving Performance With Stimulant Medication

NCT00572026
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 20, 2026, 6:15 AM EDT